Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
CDC25B-IN-2
Cat. No.:
0225LY-0620
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Add to basket
Product Overview
Description:
BIA is an agent that disrupts the interaction between mTORC2 and TMBIM6, effectively preventing AKT activation and slowing the development of cancer.
Synonym:
134271-74-2; TMBIM6 antagonist-1; 1-(2-Aminophenyl)-3-(3-nitrophenyl)prop-2-en-1-one; 2'-Amino-3-nitro-trans-chalcone; (E)-1-(2-aminophenyl)-3-(3-nitrophenyl)prop-2-en-1-one
CAS No.:
134271-74-2
Compound CID:
11425639
Formula:
C15H12N2O3
Formula Weight:
268.27
Specification
Relative Density:
1.315 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
CDC25B-IN-2 can be used in cell cycle regulation studies to explore the inhibition of the CDC25B phosphatase.
Library Information
Target:
mTOR; TMBIM6
Receptor:
mTOR; TMBIM6
Pathways:
PI3K/Akt/mTOR signaling; Metabolism
Plate Number:
AOCL-9
Plate Location:
a6
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
65 mg/mL; 242.29 mM
